Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) — Free Cash Flow Generation Index
Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has a Free Cash Flow Generation Index of -0.44x as of September 2025. Free cash flow of CN¥-5.06 Million represents 0% of operating cash flow (CN¥11.57 Million). Explore 301211 capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Free Cash Flow Generation Index (2018–2025)
Historical FCF Generation Index trend for Hubei Biocause Heilen Pharmaceutical Co. Ltd. across 8 annual periods. For the full cash flow conversion analysis, see how efficiently does Hubei Biocause Heilen Pharmaceutical Co. generate cash.
Annual Free Cash Flow Generation for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2018–2025)
Year-by-year Free Cash Flow Generation Index for Hubei Biocause Heilen Pharmaceutical Co. Ltd.. Check Hubei Biocause Heilen Pharmaceutical Co. (301211) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | -5.93x | CN¥-44.78 Million | CN¥7.55 Million | CN¥52.33 Million | ▼ -733.5% |
| 2024 | -0.71x | CN¥-68.36 Million | CN¥96.07 Million | CN¥164.43 Million | ▼ -97.1% |
| 2023 | -0.36x | CN¥-49.47 Million | CN¥137.06 Million | CN¥186.53 Million | ▼ -151.8% |
| 2022 | 0.70x | CN¥174.84 Million | CN¥250.79 Million | CN¥75.95 Million | ▼ -16.0% |
| 2021 | 0.83x | CN¥102.92 Million | CN¥123.98 Million | CN¥21.07 Million | ▼ -6.7% |
| 2020 | 0.89x | CN¥108.28 Million | CN¥121.67 Million | CN¥13.39 Million | ▼ -2.5% |
| 2019 | 0.91x | CN¥339.98 Million | CN¥372.33 Million | CN¥32.34 Million | ▲ +36.1% |
| 2018 | 0.67x | CN¥51.11 Million | CN¥76.18 Million | CN¥25.08 Million | — |